demonstrated that the combination of high-dose radiotherapy with bempegaldesleukin (a CD122-preferential interleukin-2 pathway agonist) not only impedes the growth of irradiated tumours but also activated tumour-specific CD8+ T cells in systemic immunity, leading to the elimination of non-irradiated metastases (54). Here, IL2 is linked to neoplasm.